Inventage Lab Inc.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2022, the company is a micro/nanoparticle-based drug delivery system (DDS) platform company. Built on its long-acting injectable platform IVL-DrugFluidic, it sells the veterinary heartworm preventive 'Durahart SR-3' and holds a pipeline including the male-pattern hair loss drug IVL3001, dementia drug IVL3003, and addiction treatment IVL3004, alongside the oral peptide formulation platform IVL-PePOFluidic (applied to semaglutide). IVL3001 has completed Phase 1/2a trials in Australia and is preparing for Phase 2 in Korea, and a March 2023 license-out contract extension increased the contract value by EUR 100,000.
Products & technology
- Durahart SR-3 injectionVeterinary heartworm preventive (moxidectin)
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2022 / 1 Korean MFDS device approvals · 2016
- OrphanIVL40022022-11-17Orphan Drug designation · in development20220176171
- MFDSGraft/prosthesisRevoked2016-03-15Product approval · Class 4제허 16-197 호
R&D and key agreements
Source: DART corporate disclosureIVL3001 · 남성형 탈모 · 호주 임상1상/2a상 완료, 국내 임상2상 준비 · 1-month long-acting reformulated drug on the IVL-DrugFluidic platform; Phase 1/2a completed in Australia, Phase 2 in preparation in Korea
IVL3003 · 치매 · 호주 임상1상/2상 진행 중
IVL3004 · 마약 및 알코올 중독 · 호주 임상1상 Top line 결과 발표
IVL-PePOFluidic(세마글루타이드 경구제형) · 비만/당뇨 · 연구개발 중 · Oral peptide formulation technology based on IVL-GeneFluidic; targets higher bioavailability than Novo Nordisk's Rybelsus
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer1
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 25, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-14
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition